Heterodinuclear ruthenium(II)-cobalt(III) complexes as models for a new approach to selective cancer treatment.

Heterodinuclear ruthenium(II)-cobalt(III) complexes have been prepared as part of investigations into a new approach to selective cancer treatment. A cobalt(III) centre bearing amine ligands, which serve as models for cytotoxic nitrogen mustard ligands, is connected by a bridging ligand to a ruthenium(II)-polypyridyl moiety. Upon excitation of the ruthenium centre by visible light, electron transfer to the cobalt(III) centre results in reduction to cobalt(II) and consequent release of its ligands. We have synthesised several such structures and demonstrated their ability to release ligands upon excitation of the ruthenium centre by visible light.